Abstract
Radiation recall dermatitis is characterized by an inflammatory reaction within a previously irradiated volume after administration of a drug. Antineoplastic drugs have mainly been involved in radiation recall reactions. This phenomenon is well known but poorly understood. Many hypotheses as stem-cell depletion in the radiotherapy field, heritable mutations within surviving stem cells, local vascular changes as well as a drug hypersensitivity reaction have been proposed to explain these reactions. In this report, we describe a non-small cell lung cancer patient treated with a carboplatin plus gemcitabine combination chemotherapy as first line followed by pemetrexed as second line therapy. Twenty-five years ago, she completed radiation therapy for breast cancer. Three days after the first cycle of pemetrexed, she presented with a radiation recall dermatitis. As EGFR-staining was negative, we rechallenged the patient with pemetrexed. Unfortunately, although less intense, we faced a recurrence of the skin reaction and pemetrexed was no longer continued.
Original language | English |
---|---|
Pages (from-to) | 423-425 |
Number of pages | 3 |
Journal | Lung Cancer |
Volume | 54 |
Issue number | 3 |
DOIs | |
Publication status | Published - 1 Dec 2006 |
Externally published | Yes |
Keywords
- Chemotherapy
- Cutaneous
- Lung cancer
- Pemetrexed
- Radiation recall dermatitis
- Radiation therapy
- Side-effect
- Skin toxicity